AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12094249
Drug: Doxorubicin (DOX)
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (DOX) 30 mg/m² administered from days 1 to 3 and days 8 to 10, along with vincristine, prednisolone, cyclophosphamide, and L‐asparaginase, followed by three courses of consolidation and four courses of intensification
Trial: 2006664
Drug: Diuretics with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretics with or without methyldopa
Trial: 31501124
Drug: Probiotic tablets
RxNorm normalized name: Rezyst Probiotic
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic tablets containing Streptococcus salivarius M18 and Lactobacillus acidophilus with regular oral hygiene
Trial: 31501124
Drug: Regular oral
RxNorm normalized name: infant formula,regular ORAL PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular oral hygiene alone
Trial: 29669596
Drug: 12.5-μg sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5-μg sublingual tablets of misoprostol
Trial: 29669596
Drug: Placebo sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual tablets and 25-μg vaginal tablets of misoprostol
Trial: 15980034
Drug: Subjects with
RxNorm normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with microvascular complications and glucose level <7.7 mmol/L
Trial: 10578025
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (Group B)
Trial: 10578025
Drug: Both enteral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both enteral and parenteral nutrition (Group C)
Trial: 7485307
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (0.5 mg intracervically)
Trial: 1691900
Drug: Medium-molecular-weight hydroxyethyl
RxNorm normalized name: chitosan medium molecular weight (200-800 MPA.S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-molecular-weight hydroxyethyl starch solution
Trial: 1691900
Drug: Low-molecular-weight hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight hydroxyethyl starch solution
Trial: 374194
Drug: Oral BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BCG vaccine
Trial: 8835890
Drug: Acid-reducing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid-reducing therapy (all drugs)
Trial: 1575589
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg, intramuscular injection)
Trial: 1575589
Drug: Placebo (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intramuscular injection)
Trial: 3909329
Drug: Aztreonam, 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam, 2.0 g every 8‐12 hr
Trial: 29370583
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in ER-positive or luminal tumours
Trial: 22990330
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg almorexant once daily for 9 days
Trial: 11190775
Drug: 0.1% dimetindene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% dimetindene maleate spray (Fenistil Nasal Dosierspray)
Trial: 3057674
Drug: Oral prazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prazosin (2 mg twice daily) for three weeks
Trial: 26376765
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of mupirocin (three times a day)
Trial: 26376765
Drug: Topical administration
RxNorm normalized name: Octocaine 5 % Ointment for Oral and Topical Administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of mupirocin (once a day)
Trial: 24354929
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg daily) plus Ezetimibe (10 mg daily)
Trial: 20302811
Drug: Medical management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical management (non-surgical conventional treatment)
Trial: 12207597
Drug: Dithranol short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dithranol short contact therapy
Trial: 10476894
Drug: Naproxen 500
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg twice daily for one week with bioabsorbable membrane
Trial: 8229546
Drug: Timed-release 5-ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timed-release 5-ASA (50 mg/kg/day, maximum 3 g/day) for 8 weeks
Trial: 26062916
Drug: Caffeine Ingestion
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine Ingestion (6 mg/kg BW)
Trial: 23588439
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of endurance and strength training (SE; n = 22)
Trial: 20378504
Drug: Cetuximab combined
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab combined with FOLFOX6 (leucovorin 5‐fluorouracil/oxaliplatin); cetuximab at a loading dose of 400 mg/m2 followed by 250 mg/m2 weekly and FOLFOX6 regimen every 2 weeks consisting of oxaliplatin 85 mg/m2, LV 400 mg/m2, and 5‐FU bolus 400 mg/m2 followed by 5‐FU continuous infusion 2400 mg/m2 over 46 hours.
Trial: 18564988
Drug: Patients on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on calcineurin inhibitors (CNI) and azathioprine or mycophenolate mofetil
Trial: 17037284
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy (ACE inhibitors, beta-antagonists, diuretics)
Trial: 17037284
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose aspirin (300 mg/day)
Trial: 17037284
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (not specified)
Trial: 10349919
Drug: Thoracic Epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic Epidural Analgesia (TEA) with bupivacaine 0.125% and fentanyl 5 microg/ml
Trial: 10349919
Drug: Lumbar Epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar Epidural Analgesia (LEA) with morphine 0.2 microg/ml
Trial: 7575771
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg once daily, increased to target levels of LDL cholesterol between 2.3 mmol/l (90 mg/dl) and 3.6 mmol/l (140 mg/dl)
Trial: 7575771
Drug: Simvastatin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (various dosages: 40 mg, 20 mg, 10 mg, 5 mg)
Trial: 7870911
Drug: Cocaine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (2 mg/kg)
Trial: 24474396
Drug: Adoptive cell
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive cell therapy with TIL and high-dose aldesleukin after 12 Gy TBI
Trial: 20538634
Drug: Intravitreous bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreous bevacizumab (1.25 mg, three loading injections at six week intervals)
Trial: 18575048
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia (ropivacaine 0.2% 10 ml, followed by an infusion of 5 ml/h for 96 hours)
Trial: 18575048
Drug: Intravenous opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous opioid analgesia (morphine hydrochloride 0.1 mg/kg IV every 4-6 hours as needed, with or without ketorolac trometamol up to 90 mg/day IV)
Trial: 16020979
Drug: gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemcitabine plus oral etoposide (GE group)
Trial: 10493324
Drug: Gabapentin (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (900 to 1800 mg/d)
Trial: 10493324
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 to 75 mg/d)
Trial: 1775082
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta-estradiol (TTS 50) at 50 micrograms/day
Trial: 7282752
Drug: Control (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (before administration of hydralazine or isosorbide dinitrate)
Trial: 30802558
Drug: Trifarotene 50
RxNorm normalized name: Trifarotene 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifarotene 50 μg/g cream
Trial: 24241092
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (600 mg) and vitamin E (400 IU)
Trial: 21798991
Drug: One-day interval
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 1 day)
Trial: 21798991
Drug: Two-day interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 2 days)
Trial: 21798991
Drug: One-day interval
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 1 day) among women without previous vaginal deliveries
Trial: 21798991
Drug: Two-day interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 2 days) among women without previous vaginal deliveries
Trial: 21798991
Drug: One-day interval
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 1 day) when gestation exceeded 16 weeks
Trial: 21798991
Drug: Two-day interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-day interval (Mifepristone 200 mg followed by Misoprostol 400 mcg after 2 days) when gestation exceeded 16 weeks
Trial: 17584910
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy regimen consisting of vincristine (2 mg/m2), doxorubicin (90 mg/m2), cyclophosphamide (2,200 mg/m2) and ifosfamide (2,800 mg/m2/day x 5 days), etoposide (100 mg/m2/day x 5 days) over 51 weeks
Trial: 9580247
Drug: Insulin Lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Lispro (IL)
Trial: 8155220
Drug: Daily 10-minute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 10-minute perineal massage
Trial: 2837078
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g elemental phosphorus as neutral sodium‐potassium phosphate in grape juice or in water
Trial: 2837078
Drug: 1.7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.7 g NaCl in juice
Trial: 2837078
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g phosphorus in juice
Trial: 2837078
Drug: 1-1.5 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-1.5 g phosphorus
Trial: 29722944
Drug: Oral tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tadalafil once daily
Trial: 29722944
Drug: Oral tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tadalafil on demand
Trial: 29722944
Drug: Oral tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tadalafil once-daily + on-demand
Trial: 23391033
Drug: Inlay preparations,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inlay preparations, lithium‐disilicate glass‐ceramic (IPS e.max Press)
Trial: 23391033
Drug: Onlay preparations,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onlay preparations, lithium‐disilicate glass‐ceramic (IPS e.max Press)
Trial: 23391033
Drug: Inlay preparations,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inlay preparations, zirconia ceramic (ICE Zirkon)
Trial: 23391033
Drug: Onlay preparations,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onlay preparations, zirconia ceramic (ICE Zirkon)
Trial: 18728526
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g fructose
Trial: 18728526
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g fructose
Trial: 18728526
Drug: 45 g
RxNorm normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 g fructose
Trial: 16608040
Drug: Colchicine 1
RxNorm normalized name: colchicine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1 mg per day (group A)
Trial: 16608040
Drug: No antifibrotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antifibrotic agent (group B)
Trial: 1426099
Drug: High-dose Ara-C
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-dose Ara-C (HDAra-C) as a single agent for induction therapy
Trial: 1426099
Drug: High-dose Ara-C
RxNorm normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-dose Ara-C (HDAra-C) plus mAMSA
Trial: 30452713
Drug: Albendazole treatment
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole treatment (3-monthly for 1 year)
Trial: 29215519
Drug: Transcervical Foley
RxNorm normalized name: CATHETER,FOLEY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcervical Foley catheter plus oxytocin infusion
Trial: 25238439
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia (LIA) with levobupivacaine (150 mg), ketorolac (30 mg), and adrenaline (0.5 mg)
Trial: 15836710
Drug: Norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin 400 mg once daily with cisapride 20 mg twice a day
Trial: 10480285
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human erythropoietin (rHuEpo) at a dose of 300 u/kg of body weight three times a week for 6 weeks
Trial: 1919425
Drug: Adenosine infusion
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine infusion (108 +/- 6 micrograms kg-1 min-1)
Trial: 29499745
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment, traditional EA treatment with de-qi sensation, 3 times per week for 12 sessions over 4 weeks.
Trial: 29499745
Drug: Sham electroacupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham electroacupuncture treatment, without needle penetration and electrostimulation, 3 times per week for 12 sessions over 4 weeks.
Trial: 17646219
Drug: Prednisone, 2
RxNorm normalized name: PredniSONE, 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, 2 mg/kg/d up to 60 mg, on days 1 to 5
Trial: 2506702
Drug: Neogluconin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neogluconin (2.5 mg)
Trial: 2506702
Drug: Euglucon (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglucon (5 mg)
Trial: 27919627
Drug: Pemetrexed followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed followed by erlotinib (150 mg orally once daily on days 2-17)
Trial: 27919627
Drug: Pemetrexed alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed alone (500 mg/m2 intravenously on day 1)
Trial: 26033398
Drug: Clopidogrel treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel treatment without abciximab
Trial: 26033398
Drug: Clopidogrel treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel treatment with abciximab
Trial: 19692796
Drug: Ascorbate treatment
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbate treatment (intravenous vitamin C)
Trial: 19692796
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (normal saline infusion)
Trial: 16476851
Drug: Control (unchanged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (unchanged therapy)
Trial: 15379272
Drug: rhTPO 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTPO 1.0 microg/(kg x d) administered subcutaneously for up to 14 days after chemotherapy
Trial: 14964737
Drug: Intramuscular bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular bupivacaine
Trial: 8992351
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment to lower LDL cholesterol levels (with lovastatin and, if needed, cholestyramine)
Trial: 8992351
Drug: Moderate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate treatment to lower LDL cholesterol levels
Trial: 8992351
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment to lower LDL cholesterol levels
Trial: 8256082
Drug: Glypressin (intravenous)
RxNorm normalized name: Lypressin
DrugBank: Lypressin (DB14642)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glypressin (intravenous)
Trial: 3547298
Drug: Buffy coat
RxNorm normalized name: Leucocyte buffy coat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffy coat transfusions (15 mL/kg)
Trial: 23163616
Drug: Larazotide acetate
RxNorm normalized name: Larazotide
DrugBank: Larazotide (DB05645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larazotide acetate 1 mg
Trial: 23163616
Drug: Larazotide acetate
RxNorm normalized name: Larazotide
DrugBank: Larazotide (DB05645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larazotide acetate 4 mg
Trial: 23163616
Drug: Larazotide acetate
RxNorm normalized name: Larazotide
DrugBank: Larazotide (DB05645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larazotide acetate 8 mg
Trial: 11390253
Drug: alpha‐methyl‐para‐tyrosine (AMPT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐methyl‐para‐tyrosine (AMPT) 1-g doses
Trial: 11390253
Drug: promethazine (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: promethazine (active placebo) 50-mg doses
Trial: 9415535
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous methylprednisolone (1000 mg per day) for five days
Trial: 8301876
Drug: TJ-960 (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ-960 (7.5 g per day for 8 weeks)
Trial: 3771949
Drug: Uniphyl, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphyl, 800 mg four times a day (qd)
Trial: 3771949
Drug: metered-dose albuterol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metered-dose albuterol, active, 180 micrograms four times a day (qid)
Trial: 3771949
Drug: Uniphyl, 400
RxNorm normalized name: Uniphyl, 400 mg/24 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphyl, 400 mg twice daily
Trial: 3771949
Drug: Uniphyl, 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphyl, 800 mg qd; placebo, two puffs qid
Trial: 3771949
Drug: Uniphyl, 400
RxNorm normalized name: Uniphyl, 400 mg/24 hours oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniphyl, 400 mg twice daily; placebo, two puffs qid
Trial: 25588394
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg 1 time per day for 3 days
Trial: 25588394
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg 1 time per day for 7 days followed by 500 mg 1 time per week for 12 weeks
Trial: 25588394
Drug: Long-term adjunctive
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term adjunctive azithromycin
Trial: 18217152
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/day for six months
Trial: 2901125
Drug: Flupentixol 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol 1 mg
Trial: 2901125
Drug: Flupentixol 2
RxNorm normalized name: flupenthixol 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol 2 mg
Trial: 2901125
Drug: Flupentixol 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupentixol 1 mg + Diazepam 15 mg
Trial: 31032524
Drug: Magnetic-Controlled Capsule
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnetic-Controlled Capsule Endoscopy (MCE)